Cemiplimab in oncology: a review of the literature
DOI:
https://doi.org/10.12775/QS.2026.77.75787Keywords
cemiplimab, non-small cell lung cancer, cervical cancer, cutaneous squamous cell carcinoma, PD-1 receptor inhibitorAbstract
Background.Cemiplimab, a fully human antibody that blocks programmed cell death 1 (PD-1), plays a key role in the treatment of patients with advanced cancers, including non-small cell lung cancer, cutaneous squamous cell carcinoma and cervical cancer, which typically have a poor prognosis under standard therapies.
Aim.The aim of this narrative review is to analyze the use of cemiplimab in the treatment of advanced cancers: non-small cell lung cancer, squamous cell carcinoma of the skin and cervical cancer.
Material and methods.A literature search was conducted in the PubMed and Google Scholar databases using the following keywords: "cemiplimab", "PD-1 receptor inhibitor", "non-small cell lung cancer", "cervical cancer", and "cutaneous squamous cell carcinoma". The review included original studies, systematic reviews and clinical trials without specific time restrictions. The reference lists of the retrieved articles were also cross-referenced to obtain additional valuable information.
Results.Current studies provide strong evidence supporting the efficacy of cemiplimab in the treatment of advanced cancers, including non-small cell lung cancer (NSCLC), cervical cancer and squamous cell skin cancer (CSCC).
Conclusions.Cemiplimab demonstrates significant clinical benefits in treating advanced cancers such as cervical cancer, non-small cell lung cancer (NSCLC) and squamous cell skin cancer (CSCC). Further clinical investigations are warranted to fully establish its therapeutic role in oncology.
References
1. LIBTAYO (cemiplimab-) injection, for intravenous use: full prescribing information [Internet] Initial U.S. Approval: 2018 Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761097s014lbl.pdf
2. Krishnansu S. Tewari, M.D., Bradley J. Monk, M.D., et al. Survival with Cemiplimab in Recurrent Cervical CancerN Engl J Med 2022;386:544-555Available from:https://doi.org/10.1056/NEJMoa2112187
3. Danny Rischin, M.D., Sandro Porceddu, M.D., Fiona Day, M.B., et al. Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell CarcinomaN Engl J Med. 2025;393:774-785 Available from: https://doi.org/10.1056/NEJMoa2502449.
4. Neil D. Gross, M.D. David M. Miller, et al. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaN Engl J Med 2022;387:1557-1568 Available from: https://doi.org/10.1056/NEJMoa2209813
5. Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trialNature Medicine volume 28, pages2374–2380 (2022) Available from: https://www.nature.com/articles/s41591-022-01977-y
6. Michael R. Migden, M.D., Danny Rischin, M.D., Chrysalyne D. Schmults et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaN Engl J Med 2018;379:341-351 Available from:https://doi.org/10.1056/NEJMoa1805131
7. Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingJ Immunother Cancer. 2020 Jun 17;8(1):e000775. Available from:https://doi.org/10.1136/jitc-2020-000775
8. Saadettin Kilickap MD a, Ana Baramidze PhD b, Ahmet Sezer MD c et al. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1Journal of Thoracic OncologyVolume 20, Issue 7, July 2025, Pages 941-954 Available from: https://doi.org/10.1016/j.jtho.2025.03.033
9. Danny Rischin a, Marta Gil-Martin b, Antonio González-Martin c 1et al. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancerGynecologic OncologyVolume 159, Issue 2, November 2020, Pages 322-328 Available from: https://doi.org/10.1016/j.ygyno.2020.08.026
10. Ana Oaknin a, Bradley J. Monk b, Andreia Cristina de Melo c, Hee Seung Kim d, Yong Man Kim eCemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trialEuropean Journal of CancerVolume 216, 5 February 2025, 115146 Available from:https://doi.org/10.1016/j.ejca.2024.115146
11. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMADermatol 2015;151:1081-1086.Available from:https://doi.org/10.1001/jamadermatol.2015.1187
12. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012;166:1069-1080.Available from:https://doi.org/10.1111/j.1365-2133.2012.10830.x
13. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015;51:1989-2007. Available from:https://doi.org/10.1016/j.ejca.2015.06.110
14. Kauvar AN, Arpey CJ, Hruza G, Olbricht SM, Bennett R, Mahmoud BH. Consensus for nonmelanoma skin cancer treatment, part II: squamous cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg 2015;41:1214-1240. Available from:https://doi.org/10.1097/DSS.0000000000000478
15. A. Sezer, S. Kilickap, M. Gümüş, et al.Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial Lancet, 397 (2021), pp. 592-604Available from:https://doi.org/10.1016/S0140-6736(21)00228-2
16. M. Gogishvili, T. Melkadze, T. Makharadze, et al.Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial Nat Med, 28 (2022), pp. 2374-2380. Available from:https://www.nature.com/articles/s41591-022-01977-y
17. F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin., 68 (2018), pp. 394-424 Available from:https://doi.org/10.3322/caac.21492
18. R. Burk, Z. Chen, C. Saller, T.C.G.A.R. Network Integrated genomic and molecular characterization of cervical cancer Nature, 543 (2017), pp. 378-384. Available from: https://www.nature.com/articles/nature21386
19. M.A. Socinski, C. Obasaju, D. Gandara, et al. Current and emergent therapy options for advanced squamous cell lung cancer J Thorac Oncol, 13 (2018), pp. 165-183 Available from:https://doi.org/10.1016/j.jtho.2017.11.111
20. S.V. Soldera, N.B. Leighl Update on the treatment of metastatic squamous non-small cell lung cancer in New Era of personalized medicine Front Oncol, 7 (2017), p. 50Available from: https://doi.org/10.3389/fonc.2017.00050
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Alicja Piwowarczyk, Julia Białas , Joanna Paluchowska, Alicja Kodura, Przemysław Piątek, Łukasz Szymański, Milena Mordarska, Artur Merc, Jan Łozowski

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 166
Number of citations: 0